Merck & Co., Inc.
MRKHealthcare
$121.49
-1.89%
Price History (1 Year)
Market Cap
$300.4B
P/E Ratio
16.7x
P/B Ratio
5.02x
EV/EBITDA
11.8x
ROE
34.7%
FCF Yield
0.0%
Div. Yield
2.68%
DCF Value
$110.12
Overvalued vs DCF
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025-12-31 | $16.40B | $2.96B | $1.19 |
| 2025-09-30 | $17.28B | $5.79B | $2.32 |
| 2025-06-30 | $15.81B | $4.43B | $1.77 |
| 2025-03-31 | $15.53B | $5.08B | $2.02 |
AI Analysis
MRK: Pipeline Bet Gets Cheaper at 15x Earnings
- •MRK trades at 15.7x trailing PE — a discount to pharma peers that reflects the 2028 Keytruda patent cliff.
- •Full-year 2025 revenue hit $65 billion with gross margins averaging 78-80%, and forward estimates project $71 billion by 2027.
- •The Q4 2025 EPS drop to $1.19 was driven by a $5.3 billion non-operating charge, not business deterioration.
Read full analysis →
Healthcare Peers
Data provided by Financial Modeling Prep. AI analysis generated by Claude. This is not financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.